{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:24:19Z","timestamp":1788751459456,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,9,17]],"date-time":"2012-09-17T00:00:00Z","timestamp":1347840000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (Ph + ALL) are caused by the t(9;22), which fuses <jats:italic>BCR<\/jats:italic> to <jats:italic>ABL<\/jats:italic> resulting in deregulated ABL-tyrosine kinase activity. The constitutively activated BCR\/ABL-kinase \u201cescapes\u201d the auto-inhibition mechanisms of c-ABL, such as allosteric inhibition. The ABL-kinase inhibitors (AKIs) Imatinib, Nilotinib or Dasatinib, which target the ATP-binding site, are effective in Ph + leukemia. Another molecular therapy approach targeting BCR\/ABL restores allosteric inhibition. Given the fact that all AKIs fail to inhibit BCR\/ABL harboring the \u2018gatekeeper\u2019 mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The efficacy of this approach on the leukemogenic potential of BCR\/ABL was studied in Ba\/F3 cells, primary murine bone marrow cells, and untransformed Rat-1 fibroblasts expressing BCR\/ABL or BCR\/ABL-T315I as well as in patient-derived long-term cultures (PDLTC) from Ph + ALL-patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Here, we show that GNF-2 increased the effects of AKIs on unmutated BCR\/ABL. Interestingly, the combination of Dasatinib and GNF-2 overcame resistance of BCR\/ABL-T315I in all models used in a synergistic manner.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Our observations establish a new approach for the molecular targeting of BCR\/ABL and its resistant mutants using a combination of AKIs and allosteric inhibitors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-12-411","type":"journal-article","created":{"date-parts":[[2012,11,3]],"date-time":"2012-11-03T15:14:31Z","timestamp":1351955671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I"],"prefix":"10.1186","volume":"12","author":[{"given":"Afsar Ali","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Metodieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Badura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamduh","family":"Khateb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nili","family":"Ruimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Najajreh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver Gerhard","family":"Ottmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Mahajna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Ruthardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,17]]},"reference":[{"issue":"4944","key":"3328_CR1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1126\/science.2406902","volume":"247","author":"GQ Daley","year":"1990","unstructured":"Daley GQ, Van Etten RA, Baltimore D: Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome. Science. 1990, 247 (4944): 824-830. 10.1126\/science.2406902.","journal-title":"Science"},{"issue":"39","key":"3328_CR2","doi-asserted-by":"publisher","first-page":"16616","DOI":"10.1073\/pnas.0908107106","volume":"106","author":"H Haeno","year":"2009","unstructured":"Haeno H, Levine RL, Gilliland DG, Michor F: A progenitor cell origin of myeloid malignancies. Proc Natl Acad Sci U S A. 2009, 106 (39): 16616-16621. 10.1073\/pnas.0908107106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"3328_CR3","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1002\/ijc.23467","volume":"122","author":"T Beissert","year":"2008","unstructured":"Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, Ruthardt M: Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 peptide inhibits unmutated and imatinib-resistant BCR\/ABL. Int J Cancer. 2008, 122 (12): 2744-2752. 10.1002\/ijc.23467.","journal-title":"Int J Cancer"},{"issue":"12","key":"3328_CR4","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1038\/leu.2009.194","volume":"23","author":"AA Mian","year":"2009","unstructured":"Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M: Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR\/ABL. Leukemia. 2009, 23 (12): 2242-2247. 10.1038\/leu.2009.194.","journal-title":"Leukemia"},{"issue":"47","key":"3328_CR5","doi-asserted-by":"publisher","first-page":"7389","DOI":"10.1038\/sj.onc.1206942","volume":"22","author":"NP Shah","year":"2003","unstructured":"Shah NP, Sawyers CL: Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene. 2003, 22 (47): 7389-7395. 10.1038\/sj.onc.1206942.","journal-title":"Oncogene"},{"issue":"10","key":"3328_CR6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrd2324","volume":"6","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J: Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov. 2007, 6 (10): 834-848. 10.1038\/nrd2324.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"3328_CR7","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nrm1280","volume":"5","author":"O Hantschel","year":"2004","unstructured":"Hantschel O, Superti-Furga G: Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004, 5 (1): 33-44. 10.1038\/nrm1280.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3328_CR8","unstructured":"Badura S, Tesanovic T, Pfeifer H, Liebermann M, Falkenburg JHF, Ruthardt M, Ottmann OG: Differential effects of selective inhibitors targeting the PI3K\/AKT\/mTOR pathway in long-term cultures of acute lymphoblastic leukemia reveal a distinct role of mTORC2. submitted for publication"},{"issue":"3","key":"3328_CR9","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.exphem.2008.11.002","volume":"37","author":"BA Nijmeijer","year":"2009","unstructured":"Nijmeijer BA, Szuhai K, Goselink HM, van Schie ML, van der Burg M, de Jong D, Marijt EW, Ottmann OG, Willemze R, Falkenburg JH: Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol. 2009, 37 (3): 376-385. 10.1016\/j.exphem.2008.11.002.","journal-title":"Exp Hematol"},{"issue":"4\u20135","key":"3328_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0166-3542(90)90001-N","volume":"14","author":"MN Prichard","year":"1990","unstructured":"Prichard MN, Shipman C: A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 1990, 14 (4\u20135): 181-205.","journal-title":"Antiviral Res"},{"issue":"2","key":"3328_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/nchembio760","volume":"2","author":"FJ Adrian","year":"2006","unstructured":"Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, Zhang G, Hur W, Ding S, Manley P, et al: Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2006, 2 (2): 95-102. 10.1038\/nchembio760.","journal-title":"Nat Chem Biol"},{"issue":"7280","key":"3328_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nature08675","volume":"463","author":"J Zhang","year":"2010","unstructured":"Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, Sim T, Powers J, Dierks C, Sun F, et al: Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010, 463 (7280): 501-506. 10.1038\/nature08675.","journal-title":"Nature"},{"issue":"9","key":"3328_CR13","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1038\/leu.2009.69","volume":"23","author":"AA Mian","year":"2009","unstructured":"Mian AA, Schull M, Zhao Z, Oancea C, Hundertmark A, Beissert T, Ottmann OG, Ruthardt M: The gatekeeper mutation T315I confers resistance against small molecules by increasing or restoring the ABL-kinase activity accompanied by aberrant transphosphorylation of endogenous BCR, even in loss-of-function mutants of BCR\/ABL. Leukemia. 2009, 23 (9): 1614-1621. 10.1038\/leu.2009.69.","journal-title":"Leukemia"},{"issue":"10","key":"3328_CR14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nsmb.1486","volume":"15","author":"M Azam","year":"2008","unstructured":"Azam M, Seeliger MA, Gray NS, Kuriyan J, Daley GQ: Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008, 15 (10): 1109-1118. 10.1038\/nsmb.1486.","journal-title":"Nat Struct Mol Biol"},{"issue":"1","key":"3328_CR15","doi-asserted-by":"publisher","first-page":"e15929","DOI":"10.1371\/journal.pone.0015929","volume":"6","author":"RE Iacob","year":"2011","unstructured":"Iacob RE, Zhang J, Gray NS, Engen JR: Allosteric interactions between the myristate- and ATP-site of the Abl kinase. PLoS One. 2011, 6 (1): e15929-10.1371\/journal.pone.0015929.","journal-title":"PLoS One"},{"issue":"4","key":"3328_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/10428190801896103","volume":"49","author":"O Hantschel","year":"2008","unstructured":"Hantschel O, Rix U, Superti-Furga G: Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008, 49 (4): 615-619. 10.1080\/10428190801896103.","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"3328_CR17","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1128\/MCB.00246-10","volume":"30","author":"P Patwardhan","year":"2010","unstructured":"Patwardhan P, Resh MD: Myristoylation and membrane binding regulate c-Src stability and kinase activity. Mol Cell Biol. 2010, 30 (17): 4094-4107. 10.1128\/MCB.00246-10.","journal-title":"Mol Cell Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-411.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-411\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-411.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T21:13:15Z","timestamp":1630617195000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,17]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3328"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-411","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,17]]},"assertion":[{"value":"13 April 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"411"}}